Fetcroja 1 g powder for concentrate for solution for infusion

DRUG2 trials

Sponsors

Shionogi B.V., Fundacion Publica Andaluza Para La Gestion De La Investigacion En Salud De Sevilla

Conditions

Aerobic Gram-negative bacterial infectionsBacteriemia producida por P. aeruginosa.

Phase 2

A multicenter, single-arm, open-label study to assess the pharmacokinetics, safety, and tolerability of cefiderocol in hospitalized pediatric patients from birth to < 3 months of age with suspected or confirmed aerobic Gram-negative bacterial infections

WithdrawnCTIS2023-503757-35-00

Shionogi B.V.Aerobic Gram-negative bacterial infections

Target: 20Updated: 2023-10-30

Phase 4

Efficacy and safety of 7 versus 14 days of antibiotic treatment for bacteremia produced by Pseudomonas aeruginosa: a multicenter, randomized (SHORTEN-2) clinical trial with a DOOR/RADAR analysis.

Not yet recruitingCTIS2023-508441-41-00

Fundacion Publica Andaluza Para La Gestion De La Investigacion En Salud De SevillaBacteriemia producida por P. aeruginosa.

Target: 306Updated: 2025-07-25